Leveraging Catalyst Development and Process Development in Custom Manufacturing for Advanced APIs (Active Pharmaceutical Ingredients) and Intermediates


  • First Session: October 12, 2017: 11:00am EDT, 5:00pm CEST, 11:00pm CST
    Repeat Session: October 17, 2017: 9:00am CEST, 3:00pm CST, 3:00am EDT


First Session: October 12, 2017:11:00am EDT, 5:00pm CEST, 11:00pm CST
Repeat Session: October 17, 2017: 9:00am CEST, 3:00pm CST, 3:00am EDT

  • Overview

    With ever-increasing market requirements for purity and yield, catalytic reactions are of major importance for efficient manufacturing of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). This webinar validates the benefits of leveraging best in class catalyst expertise with complex synthesis process development. This leads to more efficient processes as well as improved manufacturing scale-ups for pharmaceutical intermediates and APIs. The presented case study will examine the benefits of Evonik’s combined customized catalyst development and manufacturing capabilities.

    Key Learning Objectives:

    • Understanding the importance of appropriate catalyst selection related to the efficiency of a complex synthesis process

    • The systems, processes, and procedures required for successful process development, scale-up and manufacturing

    • Gain insight into effective CMO qualification, selection and project execution

    • Avoid costly pitfalls and delays in CMO selection


    Evonik Image

    Presentation 1: “Concepts and tools for the development of heterogeneous catalytic processes” by Dr. Felix Roessler

    On average, 10-20% of all chemical steps in the synthesis of APIs and fine chemicals are heterogeneous catalytic hydrogenations. However, due to the high complexity of these reactions a significant part of their potential is often not fully tapped. This presentation shows how to maximize the outcome by addressing multidisciplinarity. The importance of an integrative approach covering organic chemistry, surface catalysis and chemical reaction engineering is discussed. Concepts, tools and guidelines are introduced to support the development of robust, economic, safe and scalable hydrogenation processes.

    Presentation 2: “Industrial case study: benefits of combining catalyst and process development for custom manufacturing of APIs” by Dr. David Voigtlaender

    Evonik Health Care and Evonik Catalysts provides a unique symbiosis of competencies for the development and manufacturing of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). A case study will illustrate the different phases of project execution from inquiry to GMP manufacturing and delivery. It will show the close collaboration required on multidisciplinary levels to maximize value for the customer.

    Brought to you by:
    • Speakers

      Dr. Felix Roessler
      Consultant - Catalysis Expert
      Ferowis GmbH
      Dr. David Voigtlaender
      Director Innovation Management
      Evonik Nutrition & Care GmbH

      Moderated by:
      Stu Borman
      Senior Correspondent
      C&EN